MedTrace Logo

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

NCT01280747 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2021-01-26

No results posted yet for this study

Summary

The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting. The randomization will occur at the physician level and not the patient level.

Conditions

  • Fibromyalgia
  • Painful Diabetic Peripheral Neuropathy

Interventions

OTHER

prior authorization

This is a naturalistic study. The physician will prescribe medication(s) as appropriate

OTHER

no prior authorization

This is a naturalistic study. The physician will prescribe medication(s) as appropriate

OTHER

prior authorization

This is a naturalistic study. The physician will prescribe medication(s) as appropriate

OTHER

no prior authorization

This is a naturalistic study. The physician will prescribe medication(s) as appropriate

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280747 on ClinicalTrials.gov